• Moleculin Biotech is trading at $0.45, up +5.16% on August 11, 2026.
  • The company announced its Q2 2026 earnings today.
  • Investor enthusiasm continues following the July 31, 2026, interim MIRACLE data, which showed a 37% composite complete remission among evaluable patients, including those who previously failed venetoclax.